{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:16:13Z","timestamp":1792790173986,"version":"4.5.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This report summarizes the final results from a randomized, placebo-controlled, phase 2b trial evaluating the safety, antibody persistence, and potential efficacy of a bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine in pregnant individuals and their infants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Maternal participants were randomized from 24 to 36 weeks\u2019 gestation to receive RSVpreF (120 or 240\u2005\u00b5g \u00b1 aluminum hydroxide) or placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This analysis included 579 pregnant individuals and their 572 infants from 4 countries (Argentina, Chile, South Africa, United States); 462 maternal participants received RSVpreF vaccine. Adverse events in the month following receipt of either RSVpreF vaccination or placebo (maternal) or birth (infant) were mostly anticipated events in pregnancy and the neonatal period. For all RSVpreF groups, combined RSV-A\/B 50% neutralizing titers peaked 2 weeks after vaccination. At delivery, geometric mean titer ratios between RSVpreF and placebo recipients' infants were 10.9 to 13.6. Transplacental transfer ratios (all groups) were 1.39 to 1.83. Neutralizing geometric mean titers remained higher in infants whose mothers received RSVpreF vs placebo through their first 6 months of life, with an estimated half-life of 39 to 44 days. In an exploratory analysis, observed efficacy (95% CI) for the combined RSVpreF groups against medically attended and severe medically attended infant RSV-associated lower respiratory tract illness through the first 180 days of life was 75% (\u221211% to 94%) and 83% (\u221248% to 99%), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>RSVpreF had a favorable safety profile and elicited robust neutralizing responses with efficient transplacental transfer. The potential to prevent infant RSV-associated lower respiratory tract illness was subsequently confirmed in the pivotal phase 3 efficacy trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov (NCT04032093).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiag378","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:37:19Z","timestamp":1784633839000},"source":"Crossref","is-referenced-by-count":2,"title":["Phase 2 Randomized Bivalent Respiratory Syncytial Virus Prefusion F Maternal Vaccine Trial: Final Safety, Antibody Persistence, and Efficacy"],"prefix":"10.1093","author":[{"given":"Eric A F","family":"Sim\u00f5es","sequence":"first","affiliation":[{"name":"Department of Pediatric Infectious Diseases, University of Colorado School of Medicine and Children's Hospital Colorado , Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7629-0636","authenticated-orcid":false,"given":"Shabir A","family":"Madhi","sequence":"additional","affiliation":[{"name":"South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit and"},{"name":"Wits Infectious Diseases and Oncology Research Institute, Faculty of Health Sciences, University of the Witwatersrand , Johannesburg ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7644-9085","authenticated-orcid":false,"given":"Kimberly J","family":"Center","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc , Pearl River, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7244-9056","authenticated-orcid":false,"given":"Alan T N","family":"Tita","sequence":"additional","affiliation":[{"name":"Center for Women's Reproductive Health and Department of Obstetrics and Gynecology, University of Alabama , Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrado","family":"Llapur","sequence":"additional","affiliation":[{"name":"Instituto de Maternidad y Ginecologia, Nuestra Se\u00f1ora de Las Mercedes , San Miguel de Tucum\u00e1n ,","place":["Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M","family":"Novoa P","sequence":"additional","affiliation":[{"name":"Hospital Padre Hurtado and Faculty of Medicine, University of Desarrollo, Santiago ,","place":["Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kena A","family":"Swanson","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc , Pearl River, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Radley","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc , Pearl River, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Gomme","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc , Pearl River, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda G","family":"Brock","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc , Pearl River, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4916-145X","authenticated-orcid":false,"given":"Daniel A","family":"Scott","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc , Pearl River, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iona","family":"Munjal","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc , Pearl River, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie B","family":"McGrory","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc , Pearl River, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6413-1718","authenticated-orcid":false,"given":"Annaliesa S","family":"Anderson","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc , Pearl River, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6518-4547","authenticated-orcid":false,"given":"William C","family":"Gruber","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc , Pearl River, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra C","family":"Gurtman","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc , Pearl River, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"2026082006164814500_jiag378-B1","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"2026082006164814500_jiag378-B2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-2600(22)00414-3","article-title":"The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study","volume":"11","author":"Wildenbeest","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026082006164814500_jiag378-B3","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1093\/infdis\/jiab611","article-title":"Phase 1\/2 randomized study of the immunogenicity, safety, and tolerability of a respiratory syncytial virus prefusion F vaccine in adults with concomitant inactivated influenza vaccine","volume":"225","author":"Falsey","year":"2022","journal-title":"J Infect Dis"},{"key":"2026082006164814500_jiag378-B4","volume-title":"Full Prescribing Information","author":"ABRYVSO (RSVpreF vaccine)","year":"2023"},{"key":"2026082006164814500_jiag378-B5","author":"Centers for Disease Control and Prevention"},{"key":"2026082006164814500_jiag378-B6","volume-title":"Summary of Product Characteristics","author":"ABRYSVO (respiratory syncytial virus vaccine [bivalent, recombinant])","year":"2023"},{"key":"2026082006164814500_jiag378-B7","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1056\/NEJMoa2106062","article-title":"Prefusion F protein-based respiratory syncytial virus immunization in pregnancy","volume":"386","author":"Sim\u00f5es","year":"2022","journal-title":"N Engl J Med"},{"key":"2026082006164814500_jiag378-B8","doi-asserted-by":"crossref","first-page":"7641","DOI":"10.1016\/j.vaccine.2018.10.087","article-title":"Establishment of the first WHO international standard for antiserum to respiratory syncytial virus: report of an international collaborative study","volume":"36","author":"McDonald","year":"2018","journal-title":"Vaccine"},{"key":"2026082006164814500_jiag378-B9","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.vaccine.2019.10.095","article-title":"Expansion of the 1st WHO international standard for antiserum to respiratory syncytial virus to include neutralisation titres against RSV subtype B: an international collaborative study","volume":"38","author":"McDonald","year":"2020","journal-title":"Vaccine"},{"key":"2026082006164814500_jiag378-B10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41541-026-01418-8","article-title":"Bivalent RSV prefusion F vaccination elicits effective neutralization of contemporary and monoclonal antibody-resistant RSV strains","volume":"11","author":"Chen","year":"2026","journal-title":"NPJ Vaccines"},{"key":"2026082006164814500_jiag378-B11","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.4161\/hv.29635","article-title":"Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants","volume":"10","author":"Forbes","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"2026082006164814500_jiag378-B12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-dose nirsevimab for prevention of RSV in preterm infants","volume":"383","author":"Griffin","year":"2020","journal-title":"N Engl J Med"},{"key":"2026082006164814500_jiag378-B13","doi-asserted-by":"crossref","first-page":"eaaj1928","DOI":"10.1126\/scitranslmed.aaj1928","article-title":"A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants","volume":"9","author":"Zhu","year":"2017","journal-title":"Sci Transl Med"},{"key":"2026082006164814500_jiag378-B14","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/INF.0000000000001916","article-title":"Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F\u2013targeting monoclonal antibody administered as a single dose to healthy preterm infants","volume":"37","author":"Domachowske","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"2026082006164814500_jiag378-B15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12916-020-01537-6","article-title":"Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries","volume":"18","author":"Li","year":"2020","journal-title":"BMC Med"},{"key":"2026082006164814500_jiag378-B16","first-page":"1244","article-title":"Economic-burden trajectories in commercially insured US infants with respiratory syncytial virus infection","volume":"221","author":"Chirikov","year":"2020","journal-title":"J Infect Dis"},{"key":"2026082006164814500_jiag378-B17","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study","volume":"390","author":"Shi","year":"2017","journal-title":"Lancet"},{"key":"2026082006164814500_jiag378-B18","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.3389\/fimmu.2019.01675","article-title":"Biology of infection and disease pathogenesis to guide RSV vaccine development","volume":"10","author":"Boyoglu-Barnum","year":"2019","journal-title":"Front Immunol"},{"key":"2026082006164814500_jiag378-B19","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants","volume":"388","author":"Kampmann","year":"2023","journal-title":"N Engl J Med"},{"key":"2026082006164814500_jiag378-B20","doi-asserted-by":"crossref","first-page":"e087850","DOI":"10.1136\/bmjopen-2024-087850","article-title":"Safety surveillance of respiratory syncytial virus (RSV) vaccine among pregnant individuals: a real-world pharmacovigilance study using the Vaccine Adverse Event Reporting System","volume":"15","author":"Alami","year":"2025","journal-title":"BMJ Open"},{"key":"2026082006164814500_jiag378-B21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/AOG.0000000000005817","article-title":"Preterm birth frequency and associated outcomes from the MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal trial of the bivalent respiratory syncytial virus prefusion F protein vaccine","volume":"145","author":"Madhi","year":"2025","journal-title":"Obstet Gynecol"},{"key":"2026082006164814500_jiag378-B22","doi-asserted-by":"crossref","first-page":"e2419268","DOI":"10.1001\/jamanetworkopen.2024.19268","article-title":"Nonadjuvanted bivalent respiratory syncytial virus vaccination and perinatal outcomes","volume":"7","author":"Son","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026082006164814500_jiag378-B23","doi-asserted-by":"crossref","first-page":"e266190","DOI":"10.1001\/jamanetworkopen.2026.6190","article-title":"Sequential safety surveillance of RSVpreF vaccination during pregnancy early in the postapproval period","volume":"9","author":"Michnick","year":"2026","journal-title":"JAMA Netw Open"},{"key":"2026082006164814500_jiag378-B24","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S1473-3099(25)00156-2","article-title":"Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina (BERNI study): a multicentre, retrospective, test-negative, case-control study","volume":"25","author":"P\u00e9rez Marc","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026082006164814500_jiag378-B25","doi-asserted-by":"crossref","first-page":"e4400","DOI":"10.1093\/cid\/ciaa951","article-title":"Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants","volume":"73","author":"Sim\u00f5es","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026082006164814500_jiag378-B26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.virol.2023.07.007","article-title":"In-vivo and human evidence for potential efficacy of therapeutic polyclonal RSV neutralizing antibodies for palivizumab-resistant RSV infections","volume":"586","author":"Ramirez","year":"2023","journal-title":"Virology"},{"key":"2026082006164814500_jiag378-B27","doi-asserted-by":"crossref","first-page":"126276","DOI":"10.1016\/j.vaccine.2024.126276","article-title":"Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: an exploratory analysis of a phase 2\/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY)","volume":"42","author":"Tuffy","year":"2024","journal-title":"Vaccine"},{"key":"2026082006164814500_jiag378-B28","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1473-3099(24)00570-X","article-title":"Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study","volume":"25","author":"Fourati","year":"2025","journal-title":"Lancet Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag378\/69806874\/jiag378.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag378\/69806874\/jiag378.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T10:16:56Z","timestamp":1787221016000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/advance-article\/doi\/10.1093\/infdis\/jiag378\/8740075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":28,"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiag378","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"article-number":"jiag378"}}